Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
906
Completed, industry sponsors, Cardiovascular and metabolic, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed906
906 trials
Showing 1 to 25, recently updated first.
- Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02768298 · 201 participants · Start Jul 12, 2016 · Primary completion Nov 25, 2019
Drug: LCZ696; Enalapril and 2 more · For: Chronic Heart Failure With Reduced Ejection Fraction
Sites: Regensburg, Germany; Dresden, Germany; Berlin, Germany · 34 sites in all
HealthTech Wound CareIndustry
NCT07172893 · 150 participants · Start Dec 10, 2025 · Primary completion Oct 1, 2026
Drug: DermaBind TL · For: Diabetic Foot Ulcer (DFU); Venous Leg Ulcer (VLU)
Sites: DeLand, Florida; Palm Beach Gardens, Florida; Sweetwater, Florida · 10 sites in all
- Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic StrokePivotal-lookingCompleted
ShionogiIndustry
NCT00200356 · 401 participants · Start Aug 31, 2004 · Primary completion Oct 31, 2006
Drug: Edaravone; Sodium Ozagrel · For: Cerebral Infarction
- Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03596450 · 1,278 participants · Start Jul 13, 2018 · Primary completion Jun 9, 2022
Drug: Semaglutide; Standard of care · For: Diabetes Mellitus, Type 2
Sites: Buena Park, California; Burbank, California; Costa Mesa, California · 181 sites in all
SanofiSanofi (SNY)
NCT05757713 · 23 participants · Start Jul 25, 2023 · Primary completion Aug 28, 2026
Drug: teplizumab · For: Diabetes Mellitus, Type 1
Sites: San Francisco, California; Aurora, Colorado; New Haven, Connecticut · 10 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06370715 · 153 participants · Start Apr 18, 2024 · Primary completion Sep 2, 2025
Drug: Insulin Lispro-aabc; Insulin Glargine · For: Diabetes Mellitus, Type 2
Sites: Hyderabad, India; Visakhapatnam, India; Royapuram, India · 12 sites in all
- A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00391027 · 261 participants · Start Dec 2006 · Primary completion Aug 2008
Drug: Insulin Glargine (Lantus®); Inhaled Human Insulin (Exubera®) · For: Diabetes Mellitus, Type 2
Sites: Bornem, Belgium; Brussels, Belgium; Genk, Belgium · 62 sites in all
- This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes MellitusPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00418522 · 413 participants · Start Mar 2007 · Primary completion Aug 2008
Drug: Insulin glargine; Inhaled Insulin (Exubera) · For: Diabetes Mellitus, Type 2
Sites: Phoenix, Arizona; Tucson, Arizona; Concord, California · 73 sites in all
- A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05035082 · 1,018 participants · Start Sep 1, 2021 · Primary completion Jun 18, 2025
Drug: semaglutide; oral glucose-lowering medications (commercially available) · For: Diabetes Mellitus, Type 2
Sites: Alhambra, California; Costa Mesa, California; La Jolla, California · 25 sites in all
- A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT06431763 · 402 participants · Start Jun 21, 2024 · Primary completion Dec 1, 2025
Drug: Inclisiran sodium; BPA · For: Hypercholesterolemia
Sites: Mannheim, Germany; Stuttgart, Germany; Lichtenfels, Germany · 55 sites in all
Hua Medicine LimitedIndustry
NCT06263348 · 2,024 participants · Start Jan 17, 2024 · Primary completion Dec 31, 2025
Drug: Dorzagliatin tablets · For: Type2diabetes
Sites: Beijing, China
SanofiSanofi (SNY)
NCT06716424 · 105 participants · Start Jan 6, 2025 · Primary completion Jun 12, 2026
Drug: iGlarLixi (insulin glargine/lixisenatide) · For: Type 2 Diabetes
Sites: Bengaluru, India; Delhi, India; Hyderabad, India · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06386419 · 65 participants · Start Nov 12, 2024 · Primary completion Jan 13, 2026
Drug: inclisiran · For: Primary Hypercholesterolemia; Mixed Dyslipidemia
Sites: Bangalore, India; Belagavi, India; Mumbai, India · 9 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00595049 · 11 participants · Start May 31, 2006 · Primary completion Dec 31, 2008
Drug: bosentan · For: Hypertension, Pulmonary
Sites: Camperdown, Australia
Eli Lilly and CompanyEli Lilly (LLY)
NCT06635057 · 166 participants · Start Oct 11, 2024 · Primary completion Apr 15, 2026
Drug: Tirzepatide · For: Type 2 Diabetes
Sites: Al Ahasa, Saudi Arabia; Alahsa, Saudi Arabia; Jeddah, Saudi Arabia · 29 sites in all
- Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04023227 · 922 participants · Start Dec 10, 2019 · Primary completion Mar 16, 2025
Drug: Sacubitril/valsartan; Enalapril · For: Chagas Disease; Heart Failure
Sites: CABA, Argentina; Ramos Mejía, Argentina; San Martín, Argentina · 79 sites in all
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03440736 · 781 participants · Start Feb 28, 2018 · Primary completion Nov 30, 2021
Drug: Secukinumab · For: Psoriasis; Metabolic Syndrome
Sites: Langenau, Germany; Munich, Germany; Darmstadt, Germany · 75 sites in all
- Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With HypercholesterolemiaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT05192941 · 1,770 participants · Start Apr 8, 2022 · Primary completion Jun 11, 2024
Drug: Inclisiran Sodium; Placebo · For: Hypercholesterolemia
Sites: Sofia, Bulgaria; Burgas, Bulgaria; Gabrovo, Bulgaria · 136 sites in all
- A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)Pivotal-lookingCompleted
WW International IncIndustry
NCT06605703 · 226 participants · Start Sep 18, 2024 · Primary completion Feb 5, 2026
Drug: Bupropion-Naltrexone; Bupropion-Naltrexone-Metformin · For: Obesity; Overweight
Sites: New York, New York
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin TherapyPivotal-lookingCompleted
Celltrion Pharm, Inc.Industry
NCT03499704 · 133 participants · Start Feb 11, 2020 · Primary completion Jan 2, 2024
Drug: Pioglitazone + Alogliptin; Alogliptin and 2 more · For: Diabetes Mellitus, Type 2
Sites: Bucheon-si, South Korea; Seongnam-si, South Korea; Suwon, South Korea · 15 sites in all
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05579249 · 500 participants · Start Jan 19, 2023 · Primary completion Nov 27, 2024
Drug: Semaglutide; Orlistat and 3 more · For: Obesity
Sites: Loma Linda, California
Tanabe Pharma CorporationIndustry
NCT02622113 · 139 participants · Start Dec 2014 · Primary completion Apr 2016
Drug: Canagliflozin (TA-7284); Insulin · For: Type 2 Diabetes Mellitus
Sites: Chugoku, Japan; Chūbu, Japan; Hokkaido, Japan · 7 sites in all
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT02220920 · 146 participants · Start Aug 2014 · Primary completion Jul 2015
Drug: Canagliflozin (TA-7284); Placebo and 1 more · For: Type 2 Diabetes Mellitus
Sites: Chugoku, Japan; Chūbu, Japan; Hokkaido, Japan · 7 sites in all
Tanabe Pharma CorporationIndustry
NCT02227849 · 71 participants · Start Aug 2014 · Primary completion Mar 2016
Drug: Canagliflozin (TA-7284); GLP-1 analogue · For: Type 2 Diabetes Mellitus
Sites: Chūbu, Japan; Hokkaido, Japan; Kanto, Japan · 4 sites in all
Tanabe Pharma CorporationIndustry
NCT00412867 · 58 participants · Start Dec 2006 · Primary completion Jun 2008
Drug: Alteplase · For: Stroke
Sites: Hokkaido, Japan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.